New study tracks brain decline in progressive MS
NCT ID NCT03455582
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study follows 66 people with primary progressive multiple sclerosis (PPMS) and healthy volunteers for two years to understand how thinking and memory change over time. Participants take cognitive tests and undergo MRI scans to see how brain tissue damage relates to mental decline. The goal is to better understand the disease, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal how cognitive decline progresses in primary progressive MS and which brain changes are responsible, pointing toward future therapies.
- What could go wrong
- This is an observational study with only 66 participants, so results may not apply to all patients. It does not test any treatment, so no direct benefit is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
66 people
The number who actually took part.
- Started
-
Sep 2018
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: PATIENTS * Male or female; * Age ≥ 18 years; * PPMS diagnosis according to McDonald 2010 criteria; * Disease duration ≤ 15 years; * Native French speaking; * Being affiliated to health insurance; * Willing to participate and to sign informed consent. HEALTHY CONTROLS * Male or Female; * Age ≥ 18 years; * Native French speaking; * Being affiliated to health insurance; * Willing to participate and to sign informed consent. Exclusion Criteria: PATIENTS * previous history of other neurological disease; * psychiatric comorbidity including severe depression according to DSM-IV; * alcohol or other addiction to toxic; * disabling visual or motor problems preventing participation to neuropsychological assessments; * change of psychotropic drug since less than one month; * contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body,claustrophobia or refusing MRI); * illiteracy, is unable to count or to read; * pregnant or breastfeeding women; * patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent). HEALTHY CONTROLS * history of neurological disease; * family history of MS; * psychiatric comorbidity including severe depression according to DSM-IV; * alcohol or other toxic addiction; * psychotropic drugs; known cognitive complaint or neuropsychological affection; * prior neuropsychological testing with the same tests less than 6 months * contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, meta fragments or foreign objects in the eyes, skin or body, claustrophobia or refusing MRI); * illiteracy, is unable to count or to read; * pregnant or breastfeeding women; * person concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple sclerosis, primary progressive are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Bordeaux
Bordeaux, France
-
CHU de Limoges
Limoges, France
-
CHU de Poitiers
Poitiers, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain scans reveal clues to uneven muscle weakness in progressive MS
- Allergy pill shows promise for MS repair in small trial
- Can a common supplement slow MS brain damage? new trial seeks answers.
- New hope for progressive MS: ocrelizumab trial targets disability
- Experimental CAR-T therapy takes on progressive MS
- Smartphone app and biobank join forces to decode MS progression